Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Feb;51(2):263–270. doi: 10.1038/bjc.1985.38

The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

J M Howat, M Harris, R Swindell, D M Barnes
PMCID: PMC1977040  PMID: 3966982

Abstract

Recurrence and survival rates were studied in 175 women with breast cancer who, until the development of recurrent disease, received no treatment other than a modified radical (Patey) mastectomy, and in whom the oestrogen (REc) and progesterone (RPc) receptor content of the primary tumour was measured. At the time of first relapse most patients received endocrine therapy. At a minimum follow-up of 58 months post menopausal patients who possessed REc had an increased relapse-free survival (RFS) (P = 0.02). When examined by node status patients with 1-3 axillary nodes containing tumour also had an improvement in RFS (P = 0.02). There was no benefit for node-negative or premenopausal patients. In 163 patients in whom RPc was measured, RFS was unaffected by the possession of this receptor regardless of the degree of node involvement or menopausal status. Patients with REc had a significantly longer survival following mastectomy than patients without it (P = 0.006). This was most marked in post-menopausal (P = 0.003) and node-positive (P = 0.03) patients. Survival following mastectomy was also increased in patients possessing RPc (P = 0.04) and again was most marked for post-menopausal patients (P = 0.01), although no difference could be identified within node subgroups. There were significant differences in the post-relapse survival of REc and RPc positive and negative patients (REc P = 0.03, RPc P = 0.001). Patients with both receptors survived approximately 37 months longer than their receptor-negative counterparts. This study failed to confirm that the measurement of REc and RPc can reliably predict early relapse in breast cancer. The greater overall survival of receptor-positive patients is mainly due to an increase in survival following relapse. This may reflect the response of receptor-positive tumours to endocrine therapy given for recurrent disease.

Full text

PDF
267

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Lippman M. E., Simon R., Thompson E. B., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep. 1979 Aug;63(8):1271–1277. [PubMed] [Google Scholar]
  2. Barnes D. M., Ribeiro G. G., Skinner L. G. Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment. Eur J Cancer. 1977 Oct;13(10):1133–1143. doi: 10.1016/0014-2964(77)90012-3. [DOI] [PubMed] [Google Scholar]
  3. Baum M. The management of advanced breast cancer. Br J Hosp Med. 1980 Jan;23(1):32, 35, 37-9. [PubMed] [Google Scholar]
  4. Bishop H. M., Blamey R. W., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979 Aug 11;2(8137):283–284. doi: 10.1016/s0140-6736(79)90295-2. [DOI] [PubMed] [Google Scholar]
  5. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med. 1983 Dec 1;309(22):1343–1347. doi: 10.1056/nejm198312013092240. [DOI] [PubMed] [Google Scholar]
  6. Cooke T., George D., Shields R., Maynard P., Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979 May 12;1(8124):995–997. doi: 10.1016/s0140-6736(79)92752-1. [DOI] [PubMed] [Google Scholar]
  7. Cooke T., George W. D., Griffiths K. Possible test for selection of adjuvant systemic therapy in early cancer of the breast. Br J Surg. 1980 Oct;67(10):747–750. doi: 10.1002/bjs.1800671018. [DOI] [PubMed] [Google Scholar]
  8. Croton R., Cooke T., Holt S., George W. D., Nicolson R., Griffiths K. Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1289–1291. doi: 10.1136/bmj.283.6302.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cutler S. J., Ardyce J. A., Taylor S. G., 3rd Classification of patients with disseminated cancer of the breast. Cancer. 1969 Nov;24(5):861–869. doi: 10.1002/1097-0142(196911)24:5<861::aid-cncr2820240502>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  10. Forrest A. P., Black R. B., Humeniuk V., Cant E. L., Hawkins R. A., Prescott R. J., Roberts M. M., Shivas A. A., Stewart H. J., Smith A. F. Preoperative assessment and staging of breast cancer: preliminary communication. J R Soc Med. 1980 Aug;73(8):561–566. doi: 10.1177/014107688007300805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Godolphin W., Elwood J. M., Spinelli J. J. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int J Cancer. 1981 Dec;28(6):677–683. doi: 10.1002/ijc.2910280604. [DOI] [PubMed] [Google Scholar]
  12. Hilf R., Feldstein M. L., Gibson S. L., Savlov E. D. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer. 1980 Apr 15;45(8):1993–2000. doi: 10.1002/1097-0142(19800415)45:8<1993::aid-cncr2820450802>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  13. Howat J. M., Barnes D. M., Harris M., Swindell R. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer. 1983 May;47(5):629–640. doi: 10.1038/bjc.1983.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hähnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979 Aug;44(2):671–675. doi: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  15. Jensen E. V. Hormone dependency of breast cancer. Cancer. 1981 May 15;47(10):2319–2326. doi: 10.1002/1097-0142(19810515)47:10<2319::aid-cncr2820471002>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  16. Johnson P. A., Bonomi P. D., Anderson K. M., Wolter J. M., Bacon L. D., Rossof A. H., Economou S. G. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep. 1983 Jul-Aug;67(7-8):717–720. [PubMed] [Google Scholar]
  17. Kinne D. W., Ashikari R., Butler A., Menendez-Botet C., Rosen P. P., Schwartz M. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer. 1981 May 15;47(10):2364–2367. doi: 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  18. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  19. Maass H., Jonat W. Steroid receptors as a guide for therapy of primary and metastatic breast cancer. J Steroid Biochem. 1983 Jul;19(1C):833–837. doi: 10.1016/0022-4731(83)90020-1. [DOI] [PubMed] [Google Scholar]
  20. Mason B. H., Holdaway I. M., Mullins P. R., Yee L. H., Kay R. G. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983 Jun;43(6):2985–2990. [PubMed] [Google Scholar]
  21. Maynard P. V., Blamey R. W., Elston C. W., Haybittle J. L., Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978 Nov;38(11 Pt 2):4292–4295. [PubMed] [Google Scholar]
  22. McGuire W. L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978 Dec;5(4):428–433. [PubMed] [Google Scholar]
  23. Nicholson R. I., Campbell F. C., Blamey R. W., Elston C. W., George D., Griffiths K. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981 Dec;15:193–199. doi: 10.1016/0022-4731(81)90275-2. [DOI] [PubMed] [Google Scholar]
  24. Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):597–598. doi: 10.1136/bmj.284.6315.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Paterson A. H., Zuck V. P., Szafran O., Lees A. W., Hanson J. Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol. 1982 Oct;18(10):937–943. doi: 10.1016/0277-5379(82)90241-3. [DOI] [PubMed] [Google Scholar]
  27. Pichon M. F., Pallud C., Brunet M., Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980 Sep;40(9):3357–3360. [PubMed] [Google Scholar]
  28. Ribeiro G., Palmer M. K. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):827–830. doi: 10.1136/bmj.286.6368.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Saez S., Cheix F., Asselain B. Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat. 1983;3(4):345–353. doi: 10.1007/BF01807587. [DOI] [PubMed] [Google Scholar]
  30. Samaan N. A., Buzdar A. U., Aldinger K. A., Schultz P. N., Yang K. P., Romsdahl M. M., Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 1;47(3):554–560. doi: 10.1002/1097-0142(19810201)47:3<554::aid-cncr2820470322>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  31. Shapiro C. M., Schifeling D., Bitran J. D., Desser R. K., Rochman H., Michel A., Shapiro R., Evans R., Kozloff M. F., Recant W. Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol. 1982 Feb;19(2):119–121. doi: 10.1002/jso.2930190216. [DOI] [PubMed] [Google Scholar]
  32. Stewart J. F., King R. J., Sexton S. A., Millis R. R., Rubens R. D., Hayward J. L. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer. 1981 Apr;17(4):449–453. doi: 10.1016/0014-2964(81)90254-1. [DOI] [PubMed] [Google Scholar]
  33. Stewart J. F., Rubens R. D., Millis R. R., King R. J., Hayward J. L. Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol. 1983 Oct;19(10):1381–1387. doi: 10.1016/0277-5379(93)90007-r. [DOI] [PubMed] [Google Scholar]
  34. Stewart J., King R., Hayward J., Rubens R. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat. 1982;2(3):243–250. doi: 10.1007/BF01806937. [DOI] [PubMed] [Google Scholar]
  35. Westerberg H., Gustafson S. A., Nordenskjöld B., Silfverswärd C., Wallgren A. Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer. 1980 Oct 15;26(4):429–433. doi: 10.1002/ijc.2910260407. [DOI] [PubMed] [Google Scholar]
  36. von Maillot K., Horke W., Prestele H. Prognostic significance of the steroid receptor content in primary breast cancer. Arch Gynecol. 1982;231(3):185–190. doi: 10.1007/BF02110117. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES